Please assess the completion status of the following clinical trial:

Trial Title: SGLT2 Inhibition and Left Ventricular Mass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. women and men ≥40 and \<80 years of age~2. patients with type 2 diabetes mellitus on stable anti-diabetic treatment for the last 3 months; at screening the following treatment conditions are allowed:~   * metformin + sulfonylurea with HbA1c ≥6.5% and ≤9.0%~  * metformin monotherapy with HbA1c ≥7.5% and ≤ 9.0%~  * metformin + dipeptidylpeptidase-IV inhibitor with ≥6.5% and ≤9.0%~3. waist circumference ≥80 cm in women or ≥94 cm in men~4. office blood pressure ≤150/95 mm Hg with a stable dose of a maximum of 4 antihypertensive medications for the last 3 months (24h ambulatory blood pressure measurement (ABPM) is allowed to check accuracy of office values; inclusion with 24h mean blood pressure ≤145/90 mm Hg is possible)~5. women without childbearing potential defined by:~   * at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy~  * hysterectomy~  * ≥ 50 years and in postmenopausal state \> 1 year~  * \< 50 years and in postmenopausal state \> 1 year with serum follicle-stimulating Hormone (FSH) \> 40 IU/l and serum estrogen \< 30 ng/l or a negative estrogen test, both at screening~6. women of childbearing potential with a negative serum pregnancy test at screening who agree to meet one of the following criteria from the time of screening, during the study and for a period of 4 days following the last administration of study medication:~   * correct use of reliable contraception methods. The following are acceptable: hormonal contraceptives (combined oral contraceptives, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release), intrauterine device (IUD/IUS) or a double barrier method, e.g. condom and occlusive cap (diaphragm or cervical/vault caps) with spermicide (foam, gel, film, cream or suppository)~  * true abstinence (periodic abstinence and withdrawal are not acceptable methods of contraception)~  * sexual relationship only with female partners~  * sterile male partners~7. signed written informed consent and willingness to comply with treatment and follow-up~8. capability of understanding the investigational nature, potential risks and benefits of the clinical trial~Exclusion Criteria:~1. diabetes mellitus type 1~2. uncontrolled diabetes mellitus type 2 with fasting glucose \> 13.3 mmol/l confirmed on a second day~3. previous treatment with insulin, glucagon-like peptide-1 analogues, or pioglitazone during the last year before screening~4. previous treatment with empagliflozin~5. acute illness at screening or randomization according to judgement by the investigator or patient~6. known or suspected hypersensitivity to empagliflozin, glimepiride or any excipients; known or suspected hypersensitivity to sulfonylureas or sulfonamides~7. history of multiple severe hypoglycemic episodes~8. any condition prohibiting MRI studies (e.g. metal implants, claustrophobia, body weight too high) including any suspected reaction after contrast agent application~9. patient actively attempted to lose weight or experienced unintentional clinically significant weight loss during the last 3 months~10. bariatric surgery or other gastrointestinal surgery procedures that induce chronic malabsorption~11. treatment with any weight loss drug in the preceding 6 months~12. planned significant changes of pre-study physical activity level during study participation~13. heart failure New York Heart Association (NYHA) III - IV~14. patients with known severe cardiovascular disease (e.g. myocardial infarction, unstable angina, stable coronary artery disease, stroke or transient ischemic attack)~15. calculated glomerular filtration rate (eGFR) \<60 ml/min/1,73 m2~16. treatment with loop diuretics~17. chronic diarrhea, any clinical signs of volume depletion or a haematocrit \> 48 % (women) and \> 53 % (men)~18. history of severe volume depletion that required medical therapy~19. chronic lower urinary tract infections (but not simple asymptomatic bacteriuria)~20. known acute or chronic liver disease or screening liver enzymes \> 3 x upper limit of normal (ULN)~21. serum potassium \< 3.6 or \> 5.0 mmol/l~22. glucose-6-phosphate dehydrogenase deficiency~23. anemia of unknown origin~24. pregnancy or lactation period~25. treatment with systemic glucocorticoids during the last 3 months before screening~26. chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs)~27. changes in thyroid hormone dosage (stable doses of thyroid hormones for the last 3 months are acceptable)~28. history of drug or alcohol abuse or current abuse~29. psychosomatic or psychiatric diseases requiring hospitalization during the last 12 months; ongoing treatment with one tricyclic or selective serotonin re-uptake Inhibitor (SSRI) antidepressant drug at a stable dose since the last 3 months is acceptable except for fluoxetine~30. medical history of cancer except for strictly localized tumors~31. any medical or surgical intervention planned for the next 7 months after randomization not allowing study participation according to the investigator´s judgment~32. current participation in any other clinical trial or participation in another clinical trial within 30 days before screening

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: EXPERIMENTAL): 25 mg/d empagliflozin + matching glimepiride placebo for 24 weeks.
- Glimepiride (Type: ACTIVE_COMPARATOR): 2 or 4 mg/d glimepiride+ matching empagliflozin placebo for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).